Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
American Journal of Otolaryngology|March 27, 2014
Necrotizing sialometaplasia of the palatal mucosa in patient with history of anorexia: review and case reportŁukasz Gilowski, Rafał Wiench, Anna Polakiewicz-Gilowska, et al.
Pharmaceuticals (Basel, Switzerland)|July 27, 2024
Locoregional Radiotherapy in Patients with Advanced Breast Cancer Treated with Cyclin-Dependent Kinase 4/6 Inhibitors Based on Real-World DataMarcin Kubeczko, Dorota Gabryś, Anna Polakiewicz-Gilowska, et al.
Journal of Clinical Medicine|March 11, 2023
Efficacy of CDK 4/6 Inhibitors and Radiotherapy in Breast Cancer Patients with Brain MetastasesMarcin Kubeczko, Michał Jarząb, Aleksandra Krzywon, et al.
Contemporary Oncology (Poznan, Poland)|June 22, 2013
Chemotherapy for gastric cancer patients - time for personalization in medicine?Elżbieta Nowara, Agnieszka Boratyn-Nowicka, Anna Polakiewicz-Gilowska, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 20, 2024
Efficacy of radiotherapy for bone metastasis in breast cancer patients treated with cyclin-dependent kinase 4/6 inhibitorsMarcin Kubeczko, Dorota Gabryś, Justyna Rembak-Szynkiewicz, et al.
Breast Cancer Research and Treatment|September 27, 2025
Baseline hemoglobin and neutrophil-to-lymphocyte ratio as prognostic biomarkers in patients with metastatic triple negative breast cancer treated with sacituzumab govitecan in second line and beyond: a real-world analysisMałgorzata Pieniążek, Anna Polakiewicz-Gilowska, Manuela Las-Jankowska, et al.
Therapeutic Advances in Medical Oncology|August 22, 2025
Weight change and BMI are not prognostic markers of survival outcomes in sacituzumab govitecan therapy for mTNBC in the Polish female cohortMałgorzata Pienia̧żek, Anna Polakiewicz-Gilowska, Manuela Las-Jankowska, et al.
Frontiers in Oncology|December 19, 2024
The role of FDG PET assessment in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 inhibitors in the second-line settingMarcin Kubeczko, Anna Polakiewicz-Gilowska, Andrea D'Amico, et al.
Cancer Chemotherapy and Pharmacology|October 4, 2025
Sacituzumab Govitecan initial dose reduction in polish patients with metastatic triple-negative breast cancer: impact on efficacy and safetyMałgorzata Pieniążek, Marcin Kubeczko, Manuela Las-Jankowska, et al.
NPJ Breast Cancer|May 10, 2026
Positron-emission tomography as a predictor of response to first-line cyclin-dependent kinase 4/6 inhibitors in patients with metastatic ER-positive HER2-negative breast cancerMarcin Kubeczko, Anna Polakiewicz-Gilowska, Andrea d'Amico, et al.
Pageof 2